In Silico/In Vitro Hit-to-Lead Methodology Yields SMYD3 Inhibitor That Eliminates Unrestrained Proliferation of Breast Carcinoma Cells

In Silico/In Vitro Hit-to-Lead Methodology Yields SMYD3 Inhibitor That Eliminates Unrestrained Proliferation of Breast Carcinoma Cells

SMYD3 is a lysine methyltransferase that regulates the expression of over 80 genes and is required for the uncontrolled proliferation of most breast, colorectal, and hepatocellular carcinomas. The elimination of SMYD3 restores normal expression patterns of these genes and halts aberrant cell prolife...

Full description

Bibliographic Details
Main Authors: Ilham M. Alshiraihi, Dillon K. Jarrell, Zeyad Arhouma, Kelly N. Hassell, Jaelyn Montgomery, Alyssa Padilla, Hend M. Ibrahim, Debbie C. Crans, Takamitsu A. Kato, Mark A. Brown
Format: Article
Language:English
Published: MDPI AG 2020-12-01
Series:International Journal of Molecular Sciences
Subjects:
hit-to-lead
in silico drug development
SMYD3
methyltransferase
Inhibitor-4
breast cancer
Online Access:https://www.mdpi.com/1422-0067/21/24/9549

Internet

https://www.mdpi.com/1422-0067/21/24/9549

Similar Items